Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

November 21, 2017 updated by: Tobira Therapeutics, Inc.

A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)

This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

48

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Miami, Florida, United States, 33126
        • SeaView Research, Inc.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Be informed of the nature of the study and have provided written informed voluntary consent.
  • Have a BMI ≥ 18.0 and ≤ 35.0 kg/m2.
  • Be in good general health with no clinically relevant abnormalities based on medical history, physical examination, clinical laboratory evaluations (clinical chemistry, hematology, urinalysis), and 12-lead ECG that, in the opinion of the Investigator, would affect subject safety.
  • Be able to communicate effectively with the Investigator and other study center personnel and agree to comply with the study procedures and restrictions.

Exclusion Criteria:

  • Any disease or condition that might affect drug absorption, metabolism, or excretion, or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease, as determined by the Investigator and, if necessary, the Sponsor's Medical Monitor.
  • History of stomach or intestinal surgery, except for fully healed appendectomy and/or cholecystectomy which will be allowed.
  • Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication.
  • History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2 histamine blockers or proton-pump inhibitors over the past 3 months.
  • History of achlorhydria, pernicious anemia, or peptic ulcers over the past 6 months.
  • Have a positive Helicobacter pylori urea breath test.
  • Known or suspected hypersensitivity or allergic reaction to any of the components of CVC, OME or FAM tablets.
  • History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin.
  • If female, is pregnant or breast feeding, or has a positive pregnancy test result prior to the first dose of study medication.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part 1 Group 1 (Cenicriviroc)
Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.
Other Names:
  • Cenicriviroc 150 mg
Active Comparator: Part 1 Group 1 (Omeprazole)
Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.
Other Names:
  • Omeprazole 20 mg
  • Omeprazole 40 mg
Experimental: Part 1 Group 2 (Cenicriviroc)
Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.
Other Names:
  • Cenicriviroc 150 mg
Active Comparator: Part 1 Group 2 (Famotidine)
Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.
Other Names:
  • Famotidine 40 mg
Experimental: Part 2 (Cenicriviroc)
Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.
Other Names:
  • Cenicriviroc 150 mg
Active Comparator: Part 2 (Omeprazole)
Part 2 (24 subjects) will receive Omeprazole from Days 11-20.
Other Names:
  • Omeprazole 20 mg
  • Omeprazole 40 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Pharmacokinetic Assessment of CVC, as measured by maximum plasma concentration (Cmax)
Time Frame: Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
Pharmacokinetic Assessment of CVC, as measured by minimum plasma concentration (Cmin)
Time Frame: Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
Pharmacokinetic Assessment of CVC, as measured by area under the plasma concentration-time curve (AUC)
Time Frame: Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of Adverse Events
Time Frame: 23 days
Evaluate adverse events
23 days
Changes from Baseline in 12-lead ECGs
Time Frame: Baseline and 23 days
Evaluate changes from baseline in 12-lead ECGs
Baseline and 23 days
Changes from Baseline in Vital Signs
Time Frame: Baseline and 23 days
Evaluate changes from baseline in vital signs, including blood pressure and pulse rate
Baseline and 23 days
Changes from Baseline in Physical Examinations
Time Frame: Baseline and 23 days
Evaluate changes from baseline in physical examinations
Baseline and 23 days
Changes from Baseline in Clinical Laboratory Tests
Time Frame: Baseline and 23 days
Evaluate changes from baseline in clinical laboratory tests including serum chemistry, hematology and urinalysis
Baseline and 23 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Star Seyedkazemi, PharmD, Tobira Therapeutics, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 31, 2016

Primary Completion (Actual)

April 11, 2016

Study Completion (Actual)

April 11, 2016

Study Registration Dates

First Submitted

February 3, 2016

First Submitted That Met QC Criteria

February 17, 2016

First Posted (Estimate)

February 18, 2016

Study Record Updates

Last Update Posted (Actual)

November 24, 2017

Last Update Submitted That Met QC Criteria

November 21, 2017

Last Verified

November 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe